Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
172 hedge funds and large institutions have $1.1B invested in Dicerna Pharmaceuticals, Inc. in 2020 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 68 increasing their positions, 53 reducing their positions, and 26 closing their positions.
28% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 53
12% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 26
1% more funds holding
Funds holding: 170 → 172 (+2)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
31% less capital invested
Capital invested by funds: $1.59B → $1.1B (-$490M)
71% less call options, than puts
Call options by funds: $3.42M | Put options by funds: $11.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$15M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$11.5M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$10.9M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$6.9M |
| 5 |
State Street
Boston,
Massachusetts
|
+$5.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$69.1M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$25.7M |
| 3 |
BM
Bridger Management
New York
|
-$20.1M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.23M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$5.43M |
DRNA Hedge Fund Activity: Q3 2020 in Review
172 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q3 2020, worth a combined $1.1B — down 31% from $1.59B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new DRNA positions and 26 closed out — a net gain of 3 holders — while 68 added to existing stakes and 53 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $15M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $69.1M sold.
- 172 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q3 2020, up from 170 in Q2 2020.
- Funds reported $1.1B of Dicerna Pharmaceuticals, Inc. stock for Q3 2020, down 31% quarter-over-quarter.
- 29 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q3 2020 and 26 closed out, a net change of +3 holders.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q3 2020 was Citadel Advisors, an estimated $15M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q3 2020 was EcoR1 Capital, an estimated $69.1M sold.
Based on aggregated 13F filings for Q3 2020.